Chou, Oscar Hou In, Lu, Lei, Chung, Cheuk To, Chan, Jeffrey Shi Kai, Chan, Raymond Ngai Chiu, Lee, Athena Yan Hiu, Dee, Edward Christopher, Ng, Kenrick, Pui, Hugo Hok Him, Lee, Sharen, and others. (2025) Comparisons of the risks of new-onset prostate cancer in type 2 diabetes mellitus between SGLT2I and DPP4I users: A population-based cohort study. Diabetes & Metabolism, 51 (1). Article Number 101571. ISSN 1262-3636. (doi:10.1016/j.diabet.2024.101571) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:107979)
The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided. (Contact us about this Publication) | |
Official URL: https://doi.org/10.1016/j.diabet.2024.101571 |
Abstract
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2I) have been suggested to reduce new-onset cancer amongst type-2 diabetes mellitus (T2DM) patients. This study aims to compare the risks of prostate cancer between SGLT2I and dipeptidyl peptidase-4 inhibitors (DPP4I) amongst T2DM patients.
Design, setting and participants: This was a retrospective population-based cohort study of prospectively recorded data on male patients with T2DM who were prescribed either SGLT2I or DPP4I between 1st January 2015 and 31st December 2020 from Hong Kong.
Methods: The primary outcome was new-onset prostate cancer. The secondary outcomes included cancer-related mortality and all-cause mortality. Propensity score matching (1:1 ratio) using the nearest neighbor search was performed and multivariable Cox regression was applied. A three-arm analysis including the glucagon-like peptide-1 receptor agonist (GLP1a) cohort was conducted.
Results: This study included 42129 male T2DM patients (median age: 61.0 years old [SD: 12.2]; SGLT2I: n = 17,120; DPP4I: n = 25,009). In the propensity score matched cohort, the number of prostate cancers was significantly lower in SGLT2I users (n = 60) than in DPP4I (n = 102). Over a follow-up duration of 5.61 years, SGLT2I was associated with lower prostate cancer risks (HR: 0.45; 95% CI: 0.30-0.70) than DPP4I after adjustments. The subgroup analyses showed that the interactions between SGLT2I and age, hypertension, heart failure, and GLP-1a were not statistically significant. The result remained consistent in the sensitivity analysis.
Conclusion: The study demonstrated SGLT2I was associated with lower risks of new-onset prostate cancer after propensity score matching and adjustments compared to DPP4I amongst T2DM patients.
Item Type: | Article |
---|---|
DOI/Identification number: | 10.1016/j.diabet.2024.101571 |
Uncontrolled keywords: | Dipeptidyl peptidase-4 inhibitors, Glucagon-like peptide-1 receptor agonist, Prostate, Prostate cancer, Sodium-glucose cotransporter 2 inhibitors |
Subjects: | R Medicine |
Divisions: | Divisions > Division of Natural Sciences > Kent and Medway Medical School |
Funders: | University of Kent (https://ror.org/00xkeyj56) |
SWORD Depositor: | JISC Publications Router |
Depositing User: | JISC Publications Router |
Date Deposited: | 24 Jan 2025 14:39 UTC |
Last Modified: | 27 Jan 2025 15:55 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/107979 (The current URI for this page, for reference purposes) |
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):